Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §102 only | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KNIGHT, TERESA E | 1 | 65.1% | +49.5% |
| CLARKE, TRENT R | 1 | 41.2% | +26.0% |
| FORD, VANESSA L | 1 | 40.1% | +38.3% |
| MOSS, NATALIE M | 1 | 31.2% | +17.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17494690 | MODULATING ISCHEMIC INJURY | CLARKE, TRENT R | 141d overdue |
| 18036815 | SECRETOME FRACTIONS AND USES THEREOF | KNIGHT, TERESA E | 58d overdue |
| 17197580 | Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 Syndrome | FORD, VANESSA L | 6d |
| 16690197 | Novel methods for delivering therapeutics agents to the eye via the nasal passages | MOSS, NATALIE M | 6d |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1651 | 1 |
| 1674 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036815 | SECRETOME FRACTIONS AND USES THEREOF | KNIGHT, TERESA E | 1634 | §103 | Non-Final OA | 58d overdue | Pending | May 12, 2023 |
| 17494690 | MODULATING ISCHEMIC INJURY | CLARKE, TRENT R | 1651 | §102 | Final Rejection | 141d overdue | Pending | Oct 05, 2021 |
| 17197580 | Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 Syndrome | FORD, VANESSA L | 1674 | §103 | Final Rejection | 6d | Pending | Mar 10, 2021 |
| 16690197 | Novel methods for delivering therapeutics agents to the eye via the nasal passages | MOSS, NATALIE M | 1653 | Other | Non-Final OA | 6d | Pending | Nov 21, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial